Botanix Pharmaceuticals Ltd (ASX: BOT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Botanix Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $273.60 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.56 billion
Earnings per share -0.008
Dividend per share N/A
Year To Date Return -5.26%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Botanix Pharmaceuticals Ltd (ASX: BOT)
    Latest News

    cannabis leaves on a rising line graph representing growth of ASX cannabis share price
    Share Market News

    Why the Botanix (ASX:BOT) share price is flying 6%

    The Botanix (ASX:BOT) share price is on the rise today after the company released its quarterly report to the ASX.…

    Read more »

    rocketing asx share price represented by man riding golden dollar sign speeding through clouds
    Share Market News

    Why the Botanix (ASX:BOT) share price rocketed 22% to a record high today

    The Botanix Pharmaceuticals Ltd (ASX:BOT) share price is rocketing higher again on Wednesday. Here's why it hit a record high...

    Read more »

    A medical researcher works on a bichip, indicating share price movement in ASX tech companies
    Share Market News

    Why the Botanix (ASX:BOT) share price is soaring up today

    The Botanix (ASX: BOT) share price is surging higher today on news the company has completed its phase 2a clinical…

    Read more »

    Share Market News

    Why the Botanix (ASX:BOT) share price is 15% higher today

    The Botanix Pharmaceuticals Ltd (ASX: BOT) share price shot up 15% higher today on news of a positive update in…

    Read more »

    Share Market News

    The Botanix (ASX:BOT) share price is soaring 15% higher today. Here's why.

    The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is soaring higher today following the release of its September quarter update.

    Read more »

    soaring hydrix share price represented by doctor riding on top of heart high up in the clouds
    ⏸️ Investing

    Why I think these small cap ASX shares will perform in 2021

    The ASX is littered with lots of companies that show potential to become the next market darling. Here are my…

    Read more »

    Share Market News

    This ASX cannabis share just hit a milestone

    The Botanix share price surged 20% higher today following the company's announcement of a milestone achievement but has since been…

    Read more »

    a woman
    Share Market News

    What's in store for these 4 ASX cannabis shares in 2020?

    2019 was a bear market for cannabis stocks globally. We take a look at what 2020 holds for ASX cannabis…

    Read more »

    a woman
    Healthcare Shares

    How did these ASX cannabis shares perform in 2019?

    This year was a difficult one for ASX cannabis shares as well as cannabis stocks globally with share prices worldwide…

    Read more »

    a woman
    Share Gainers

    Why these ASX cannabis shares are starting the week on a high

    Cannabis shares AusCann Group Holdings Ltd (ASX:AC8) and Botanix Pharmaceuticals Ltd (ASX:BOT) are on a high on Monday. Here's why...

    Read more »

    a woman
    Share Market News

    Which ASX cannabis shares should you buy in November?

    Marijuana shares were hot favourites earlier this year but have suffered as investors revaluate the sector. Here we look at…

    Read more »

    a woman
    Share Market News

    The cannabis collapse: ASX marijuana shares going cheap

    Investors have pulled back from marijuana shares as the sector begins to mature and the adverse publicity surrounding vaping takes…

    Read more »

    BOT ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Botanix Pharmaceuticals Ltd

    Botanix Pharmaceuticals Ltd is a clinical-stage cannabinoid therapeutics company. The company's focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietarydrug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne. The majority of Revenue is Derived from Australia.

    BOT Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    28 Feb 2024 $0.18 $-0.01 -5.56% 1,405,689 $0.18 $0.18 $0.18
    27 Feb 2024 $0.18 $0.00 0.00% 1,130,816 $0.19 $0.19 $0.18
    26 Feb 2024 $0.18 $-0.01 -5.41% 1,337,113 $0.19 $0.19 $0.18
    23 Feb 2024 $0.19 $0.01 5.56% 1,440,692 $0.18 $0.19 $0.18
    22 Feb 2024 $0.18 $-0.01 -5.41% 1,593,189 $0.19 $0.19 $0.18
    21 Feb 2024 $0.19 $-0.01 -5.26% 4,850,338 $0.19 $0.19 $0.18
    20 Feb 2024 $0.19 $-0.01 -5.13% 2,405,610 $0.19 $0.20 $0.19
    19 Feb 2024 $0.20 $0.00 0.00% 1,291,115 $0.20 $0.20 $0.19
    16 Feb 2024 $0.20 $0.01 5.26% 2,188,045 $0.19 $0.20 $0.19
    15 Feb 2024 $0.19 $0.00 0.00% 733,103 $0.19 $0.19 $0.19
    14 Feb 2024 $0.19 $0.00 0.00% 911,289 $0.19 $0.19 $0.19
    13 Feb 2024 $0.19 $0.00 0.00% 1,689,702 $0.19 $0.20 $0.19
    12 Feb 2024 $0.19 $0.01 5.41% 1,449,847 $0.19 $0.20 $0.19
    09 Feb 2024 $0.19 $-0.01 -5.26% 671,798 $0.19 $0.19 $0.19
    08 Feb 2024 $0.19 $0.01 5.41% 1,365,297 $0.19 $0.19 $0.19
    07 Feb 2024 $0.19 $-0.01 -5.26% 2,185,447 $0.19 $0.20 $0.19
    06 Feb 2024 $0.19 $0.02 11.43% 5,960,977 $0.18 $0.20 $0.18
    05 Feb 2024 $0.18 $-0.01 -5.56% 2,345,501 $0.18 $0.18 $0.18
    02 Feb 2024 $0.18 $0.01 5.71% 610,603 $0.18 $0.18 $0.18
    01 Feb 2024 $0.18 $0.00 0.00% 1,007,804 $0.17 $0.18 $0.17
    31 Jan 2024 $0.17 $0.00 0.00% 2,941,582 $0.17 $0.18 $0.17
    30 Jan 2024 $0.17 $0.00 0.00% 5,342,404 $0.17 $0.17 $0.17

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    18 May 2023 Matthew (Matt) Callahan Buy 1,166,667 $99,166
    Conversion of securities.
    18 May 2023 Vince Ippolito Buy 2,000,000 $170,000
    Conversion of securities.
    18 May 2023 H. William Bosch Exercise 500,000 $42,500
    Conversion of securities. 500,000 Performance Rights
    18 May 2023 H. William Bosch Buy 500,000 $42,500
    Conversion of securities.
    18 May 2023 Matthew (Matt) Callahan Exercise 1,166,667 $99,166
    Conversion of securities. 1,166,667 Performance Rights
    18 May 2023 Vince Ippolito Exercise 2,000,000 $170,000
    Conversion of securities. 2,000,000 Performance Rights
    20 Mar 2023 Matthew (Matt) Callahan Buy 1,166,666 $113,166
    Conversion of securities.
    20 Mar 2023 Vince Ippolito Buy 2,000,000 $194,000
    Conversion of securities.
    20 Mar 2023 Stewart Washer Transfer 321,551 $31,190
    Off-market transfer. Assuming off-market transfer of shares
    20 Mar 2023 Stewart Washer Buy 333,333 $32,333
    Conversion of securities.
    20 Mar 2023 H. William Bosch Buy 500,000 $48,500
    Conversion of securities.
    20 Mar 2023 Daniel Sharp Buy 333,333 $32,333
    Conversion of securities.
    20 Mar 2023 Daniel Sharp Buy 282,829 $27,434
    Exercise of options.
    20 Mar 2023 Daniel Sharp Exercise 1,000,000 $97,000
    Exercise of options.
    20 Mar 2023 Vince Ippolito Exercise 2,000,000 $194,000
    Conversion of securities. 4,000,000 Performance rights
    20 Mar 2023 Stewart Washer Exercise 333,333 $32,333
    Conversion of securities. 666,667 Performance Rights
    20 Mar 2023 H. William Bosch Exercise 500,000 $48,500
    Conversion of securities. 1,000,000 Performance Rights
    20 Mar 2023 Stewart Washer Transfer 321,551 $31,190
    Off-market transfer. Assuming off-market transfer of shares
    20 Mar 2023 Daniel Sharp Exercise 333,333 $32,333
    Conversion of securities. 666,667 Performance Rights
    20 Mar 2023 Matthew (Matt) Callahan Exercise 1,166,666 $113,166
    Conversion of securities. 2,333,334 Performance Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Matthew (Matt) Callahan Executive Director Feb 2020
    Mr Callahan is an experienced life sciences executive based in Philadelphia. He is a founder of Botanix and co-inventor of many of the Company's Permetrex enabled products. Mr Callahan was the founding CEO of Churchill Pharmaceuticals and developed Yonsa through FDA approval and subsequent sale to Sun Pharmaceuticals. He was also founding CEO of drug delivery company iCeutica Inc which developed 4 FDA approved products and was sold to US private equity investors. He has more than 25 years legal, IP and investment management experience.
    Dr Stewart James Washer Non-Executive Director Feb 2019
    Dr Washer has CEO and experience in medical biotech and cannabinoid companies. Dr Washer has held a number of board positions in the past, including chairman of Hatchtech Pty Ltd that was sold in 2015 for A$279m and was a director of iCeutica that was sold to US private equity investors. He was also a Senator with Murdoch University and was a director of AusBiotech Ltd.
    Dr H. William Bosch Executive Director Jul 2016
    Dr Bosch is an accomplished pharmaceutical executive with more than 30 years of experience and industry leadership in pharmaceutical R&D. Dr. Bosch served as CSO of iCeutica where he was the principal architect of SoluMatrix drug delivery technology, used in four FDA approved prescription drug products. Earlier in his career Dr. Bosch was a pioneer in the application of nanotechnology to pharmaceutical product development. He served as a co founder of NanoSystems LLC in 1995 and co-inventor of NanoCrystal Technology, leading to the successful development and FDA approval of seven prescription drug products for a variety of indications and routes of administration.
    Mr Vince Ippolito PresidentExecutive ChairmanExecutive Director May 2019
    Mr Ippolito has more than 30 years of experience in the pharmaceuticals industry, including over 20 years' experience in dermatology. He recently served as President and Chief Operating Officer of Dermavant Sciences, a biopharmaceutical company that is commercialising products which treat inflammatory skin diseases and medical dermatologic conditions. Mr Ippolito also sits on the Board of Suneva Medical, a privately held regenerative aesthetics company. Prior to his role at Dermavant Sciences, Mr Ippolito served as the Chief Commercial Officer and Executive Vice President of Anacor Pharmaceuticals, a dermatology-based biopharmaceutical company. During his time at Anacor he was responsible for building the marketing and sales functions, and developing the company's product portfolio, as well as playing a key role in the US$5.2bn sale to Pfizer. Earlier in his career, Mr Ippolito launched multiple new dermatology products during his tenure at Medicis Pharmaceutical Corporation, an industry-leading dermatology company. Mr. Ippolito served in multiple key executive roles, including Chief Commercial Officer, General Manager of Dermatology products, Senior Vice President of North American Sales and Executive Vice President, Sales and Marketing. Mr Ippolito played a key role in the sale of Medicis to Valeant for US$2.6bn in 2012 and he went on to serve as Senior Vice President, General Manager, Aesthetics
    Mr Daniel Sharp Non-Executive Director Mar 2022
    Mr Sharp is an investment banker with more than 30 years' experience in capital markets globally, advising the boards of technology and healthcare-based organisations. He also has a network of institutional and private wealth investors globally. Mr Sharp was a Corporate Finance Executive Director of Canaccord Genuity and has previously spearheaded the Corporate Finance departments at both Shaw and Partners and Lodge Partners.
    Ms Susan Patricia Park Company Secretary Apr 2023
    -
    Dr Howie McKibbon Chief Executive Officer Aug 2023
    -
    Howie McKibbon Chief Executive Officer
    -
    Susan Patricia Park Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    National Nominees Limited 139,690,538 9.83%
    Shenasaby Investments Pty Ltd <The Shenasaby A/C> 74,586,791 5.25%
    Caperi Pty Ltd <Caperi A/C> 52,573,784 3.70%
    Citicorp Nominees Pty Limited 51,527,974 3.63%
    Dr Henry William Bosch 18,836,702 1.33%
    Zenith Pacific Limited 17,972,222 1.26%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 17,303,656 1.22%
    J P Morgan Nominees Australia Pty Limited 17,007,647 1.20%
    Hsbc Custody Nominees (Australia) Limited 16,843,169 1.19%
    Bnp Paribas Noms Pty Ltd <Drp> 14,818,037 1.04%
    Ubs Nominees Pty Ltd 14,148,149 1.00%
    Yarraandoo Pty Ltd <Yarraandoo Super Fund A/C> 13,000,000 0.91%
    Moffatt Investments Pty Ltd <Matthew Moffatt Family A/C> 10,560,000 0.74%
    Lightview Asset Pty Ltd 9,350,000 0.66%
    Zanya Nominees Pty Ltd<Jls Superannuation A/C> 8,984,545 0.63%
    Mr Vincent Peter Ippolito 8,801,644 0.62%
    Rollo Corp Property Holdings Pty Ltd <Rollo Corp Property A/C> 8,500,000 0.60%
    Mr Gary Charles Jones &Mrs Stephanie May Jones <G & S Jones Super Fund A/C> 8,000,000 0.56%
    343 Pty Ltd <343 Capital A/C> 7,125,667 0.50%
    Mr Stephane Nicolas Fayd Herbe <Fayd'Herbe Family A/C> 7,113,141 0.50%

    Profile

    since

    Note